Initial results of an optimized perfusion system.

BACKGROUND: In order to reduce the negative effects of extracorporeal circulation (ECC), the perfusion system and management were optimized at our institution. The goals of optimization were a reduction in the priming volume, in the foreign surface area and in microbubble activity, as well as optimization of suction blood management. METHODS: Sixty patients were included in this retrospective study. Patients were assigned to two groups, with regard to the use of an optimized perfusion system (OPS-group, n=30) and a standard perfusion system (SPS-group, n=30). All patients underwent elective procedures. RESULTS: There were no significant differences with respect to patient demographics and operation time. ECC time and cross-clamp time were significantly longer in the OPS group. Statistically significant differences in outcome between the two groups were seen with regard to the following variables: effective priming volume (OPS: 775±447ml; SPS: 1610±0ml; p<0.0001), hemoglobin drop after the start of ECC (OPS: 2.7±1.2g/dl; SPS: 4.2±0.8g/dl; p<0.0001), c-reactive protein on postoperative day 2 (OPS: 121.0±59.4 U/l; SPS: 164.0±50.2 U/l; p=0.003). With regard to the use of blood transfusions, a 33% reduction in the overall amount of transfused units was seen. The rate of patients without transfusions during the entire hospital stay increased from 37% (SPS) to 53% (OPS). The mean transfused red blood cell units per patient was lower in the OPS-group (1.6±2.4 units) than in the SPS-group (2.3±3.5 units). CONCLUSION: With the described optimized perfusion system, a significantly lower priming volume, leading to less hemodilution after the onset of CPB, was achieved. The amount of blood transfusions and the inflammatory response were reduced.

Retrospective analysis of outcome data with regards to the use of Phisio®-, Bioline®- or Softline®-coated cardiopulmonary bypass circuits in cardiac surgery.

BACKGROUND: Numerous cardiopulmonary bypass circuits with various coatings designed to reduce the inflammatory response and to provide better hemocompatibility are available. The aim of this study was to compare the effect of phosphorylcholine-coated, albumin-heparin-coated and synthetic polymer-coated perfusion tubing systems on patient outcome. METHODS: We performed a retrospective database review of elective patients between January 1st 2010 and December 31st 2010. Demographics, preoperative, operative, postoperative data and follow-up were collected and statistically analysed. RESULTS: We identified 201 patients and formed three groups: Group 1 with phosphorylcholine coating (n=133), Group 2 with albumin-heparin coating (n=32) and Group 3 synthetic polymer coating (n=36). Mean age was 68 ± 11 years, additive Euroscore 5.8 ± 2.7. In-hospital outcomes were comparable between the groups without statistically significant differences. The overall 30-day and 1-year late survival were 98.5% and 96.7 ± 1.9%, respectively. CONCLUSIONS: Our findings suggest that in-hospital and follow-up outcomes are comparable in cardiac surgery patients after using either phosphorylcholine-coated, albumin-heparin-coated or synthetic polymer-coated circuits during cardiopulmonary bypass.

In vitro evaluation of the CeVOX continuous central venous oxygenation monitoring system.

We investigated the in vitro performance of the CeVOX system for continuous monitoring of central venous oxygen saturation by spectrophotometry (Pulsion Medical Systems, Munich, Germany). Oxygen inflow into the system was varied, and oxygen saturation values measured by CeVOX were documented. Blood samples were simultaneously taken to assess oxygen saturation by co-oximetry, and values were compared by Bland-Altman analysis. Sixty-six data pairs were obtained at CeVOX and co-oximetry values of 16-99% and 5.5-100%, respectively. Overall, CeVOX values only slightly overestimated co-oximetry values (mean bias +2.4%), but limits of agreement (2 SD of bias) were wide (-11.8 to +16.6%). Saturation measured by CeVOX underestimated that measured by co-oximetry at higher oxygen concentrations and overestimated it at lower oxygen concentrations. There was a nearly linear correlation of the mean bias, suggesting a systematic error. We conclude that the current version of the CeVOX system does not reliably reflect oxygen saturation.

Performance of automated air tonometry under hypothermia.

Intestinal tonometry is used during hypothermic cardio-pulmonary bypass surgery to assess splanchnic perfusion. In an in vitro set-up the performance of automated air tonometry (TONOCAP) was tested for normo- and hypothermia. A 14-FG tonometry catheter was built into a testing chamber (100 cm(3)) perfused with blood from a cardio-pulmonary bypass circuit with P(a)co(2) held at 5.6-5.8 kPa (alpha-stat). P(r)co(2) from the balloon of the tonometry catheter was measured at intervals of 10 min at 37 degrees C and at 25 degrees C by the TONOCAP. Bias (precision) of P(r)co(2) - P(a)co(2 alpha-stat) and P(r)co(2) -P(a)co(2 pH-stat) at 37 degrees C blood temperature were low at 0.23 kPa (0.21) each. Tonometrically measured P(r)co(2) at 25 degrees C significantly differed from P(a)co(2 alpha-stat) bias (precision) of 2.00 kPa (0.11) but was similar to P(a)co(2 pH-stat) (0.30 kPa (0.11)). P(r)co(2) values as measured by the TONOCAP represent pH-stat approach. Identical blood gas management (pH- or alpha-stat) should be used for calculation of mucosal-arterial CO(2) difference (P(r-a)co(2) gap) or calculation of intramucosal pH.

LMP polymorphisms do not influence disease expression in psoriatic arthritis.

OBJECTIVES: To investigate the potential role of the HLA-linked LMP2 (low molecular weight protein) and LMP7 gene polymorphisms in conjunction with HLA class I and class II genes on the disease pattern in individuals with psoriatic arthritis (PsA). METHODS: Sixty-three patients with PsA and 99 unrelated controls were typed for HLA-class I and II antigens. LMP2 and LMP7 polymorphisms were determined by PCR and subsequent single stranded conformation polymorphism (SSCP) analysis or restriction enzyme digestion. RESULTS: PsA was associated with B27 (p < 0.0004), B57 (p < 0.002) and Cw2 (p < 0.008). Spondylarthritis was strongly associated with HLA-B27 (p < 0.000001), Cw2 (p < 0.0003) and DR4 (p < 0.008). For the polyarthritic pattern the only association was with B57 (p < 0.007). There was no association between the LMP2 or LMP7 genotypes and any particular disease pattern. CONCLUSIONS: These findings do not support an involvement of the HLA linked LMP2 and LMP7 gene polymorphisms in disease expression in psoriatic arthritis in addition to the known HLA class I and II associations.

TAP-polymorphisms in juvenile onset psoriasis and psoriatic arthritis.

Juvenile onset psoriasis is strongly associated with the HLA-class I genes Cw6 and B57 whereas patients with psoriatic arthritis show an increased frequency of HLA-B27. It is unclear whether additional major histocompatibility genes also increase disease susceptibility. The TAP genes (transporter associated with antigen processing) encode two membrane-spanning proteins that translocate antigenic peptides from the cytoplasm into the endoplasmic reticulum. Comparison of 60 patients with juvenile onset psoriasis, 63 psoriatic arthritis patients, and 101 caucasoid controls revealed an increase of the TAP1*0101 allele in the psoriasis group, that could not be explained by linkage to other investigated HLA genes. There were no differences for TAP2 alleles.